search button
Open Access

Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients

  • Authors:
    • Lina Chai
    • Jinjun Liu
    • Yapei Zhang
    • Mengying Zhang
    • Zhenzhen Wang
    • Yiping Wu
    • Zhichao Bai
    • Zhenpeng Qin

  • View Affiliations

  • Published online on: September 27, 2023     https://doi.org/10.3892/etm.2023.12229
  • Article Number: 530

  • Copyright: © Chai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Bivalirudin, as a direct thrombin inhibitor, is considered to be safer compared with other anticoagulants, such as heparin; however, relevant data in China are unclear. The present study aimed to compare the safety of bivalirudin and heparin as anticoagulants in Chinese patients who underwent percutaneous coronary intervention (PCI). In the present study, 2,377 patients with ST‑segment elevation myocardial infarction (STEMI), unstable angina, non‑STEMI or stable coronary artery disease who underwent primary PCI while receiving bivalirudin or heparin (low molecular weight heparin or unfractionated heparin) were reviewed, and then analyzed as the bivalirudin group (n=944) and heparin group (n=1,433). The net adverse clinical events (NACEs) within 30 days were obtained, which were defined as major adverse cardiac and cerebral events (MACCEs) + Bleeding Academic Research Consortium (BARC) grade 2‑5 bleeding events. Compared with the heparin group, the incidence of NACEs was reduced in the bivalirudin group (9.3 vs. 13.4%; P=0.003). However, no discrepancy was found in the incidence of MACCEs between the groups (5.9 vs. 7.6%; P=0.116). Moreover, the incidences of BARC 2‑5 (4.8 vs. 8.7%; P<0.001) and BARC 3‑5 bleeding events (1.9 vs. 4.4%; P=0.001) were decreased in the bivalirudin group compared with the heparin group. Following adjustment using multivariate logistic regression analysis, bivalirudin treatment (vs. heparin treatment) was independently associated with lower risks of NACEs [odds ratio (OR), 0.587; P<0.001], MACCEs (OR, 0.689; P=0.041) and BARC 2‑5 (OR, 0.459; P<0.001) and 3‑5 bleeding events (OR, 0.386; P=0.002). Overall, the present study demonstrated that bivalirudin decreased the risks of NACEs and bleeding events compared with heparin in Chinese patients who undergo PCI. However, further validation is required.
View References

Related Articles

Journal Cover

November-2023
Volume 26 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Chai L, Liu J, Zhang Y, Zhang M, Wang Z, Wu Y, Bai Z and Qin Z: Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients. Exp Ther Med 26: 530, 2023
APA
Chai, L., Liu, J., Zhang, Y., Zhang, M., Wang, Z., Wu, Y. ... Qin, Z. (2023). Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients. Experimental and Therapeutic Medicine, 26, 530. https://doi.org/10.3892/etm.2023.12229
MLA
Chai, L., Liu, J., Zhang, Y., Zhang, M., Wang, Z., Wu, Y., Bai, Z., Qin, Z."Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients". Experimental and Therapeutic Medicine 26.5 (2023): 530.
Chicago
Chai, L., Liu, J., Zhang, Y., Zhang, M., Wang, Z., Wu, Y., Bai, Z., Qin, Z."Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients". Experimental and Therapeutic Medicine 26, no. 5 (2023): 530. https://doi.org/10.3892/etm.2023.12229